Curr Opin Immunol. 2025 Aug 14;96:102643. doi: 10.1016/j.coi.2025.102643. Online ahead of print.
ABSTRACT
Autoimmune skin diseases (AISDs) constitute a group of skin disorders driven by B cell-mediated autoimmunity or dysregulation of other immune cell populations. AISD can be further divided into systemic autoimmune disease with skin involvement, such as systemic lupus erythematosus (SLE), and skin-specific autoimmune disease, such as pemphigus vulgaris (PV). Due to autoreactivity, B cells and autoantibody production play a pivotal role in B cell-driven AISDs. B cell-targeted therapies have become a major focus in research and clinical practice. Recent strategies targeting various B cell have shown promise, whereas several challenges remain in the clinical application. Patient heterogeneity results in variable therapeutic outcomes. Additionally, prolonged B cell suppression increases the risk of infections. Here, this review outlines the B cell-targeted therapeutic approaches in AISDs, explore the implications of their variable efficacy, and discuss future directions for development. We aim to provide broader perspectives for advancing targeted therapies in AISDs.
PMID:40816134 | DOI:10.1016/j.coi.2025.102643